We need combination treatments to help win the fight against cancer.

Cancer is made up of more than 200 different diseases, many of which are too complex to tackle with single drug treatments. Patients deserve more than lottery odds of finding the right combinations.

About Us

KYAN’s mission is to unlock the full potential of combination therapies, addressing unmet needs where monotherapies and single target development efforts fail.

RATIONAL
From years of research and validation, we have crafted a streamlined approach to find safe and effective combinations from endless possibilities.

Our patented computational methodology works to overcome low success rates and the soaring costs of combination development based on serendipity, convenience, and incomplete knowledge.

RELEVANT
We use data from efficiently designed experiments. For each case, we ask the question: What is the best combination? We obtain a faster, more accurate answer by looking at prospective data rather than sifting through mounds of information that already exists and is mostly irrelevant.

REAL
We validate our results against disease models from in vitro to human. Our platform has been used for successful interventional combination treatment for real-life patients.

OPTIM.AI PLATFORM

Intelligent drug-dose optimization of combinations for those who truly need it

Combination Design

Going beyond screening 2-drug combos and synergistic modeling. Optim.AI’s powerful analytics pinpoint all actionable combinations based on safety-efficacy profiles.

Prioritization

Accurately quantified responses and rankings function to correctly gauge relative efficacy and safety of combo therapies, for insight on which targets and indications are worth pursuit.

Dosage Optimization

Quick determination of clinically optimal dosing streamlines the trial process. We maximize effectiveness and minimize toxicity to avoid trial failure.

Precision Medicine

Identification of subtype-specific drug-dose ratios for correct subgroup dosing occurs through precise prediction of responders and non-responders.

News

KYAN Therapeutics Exclusively Licenses Small Molecule

We acquired the rights to develop promising HDAC inhibitors for AI-powered cancer drug development. Read more in our press release: […]

AI Platform Aids Treatment for Relapsed Lymphoma

An application of our technology was recently featured in The Straits Times. You can read more about it here: https://www.straitstimes.com/singapore/ai-platform-aids-treatment-for-relapsed-lymphoma.

Global Release of Powbab Liver Cleanse Detox

KYAN Therapeutics, in partnership with Powbab, a superfood company for better health, has developed an optimized health supplement to help […]

RECENT PUBLICATIONS

Our Team Members

Dean Ho

Dean Ho

Co-Founder
Edward Chow

Edward Chow

Co-Founder
Chih-Ming Ho

Chih-Ming Ho

Co-Founder
Xian Ting Ding

Xian Ting Ding

Co-Founder
Lisa Chow

Lisa Chow

COO / General Counsel
Masturah Rashid

Masturah Rashid

Head, Research and Development
Shane Low

Shane Low

Head, Business Development

Our Advisors

Craig Lan

Craig Lan

VP, Product Management at Champion Healthcare Technologies
Carl Firth

Carl Firth

Founder and CEO at ASLAN Pharmaceuticals
Wee Joo Chng

Wee Joo Chng

Director at National University Cancer Institute, Singapore
Jeffrey Lu

Jeffrey Lu

Co-Founder and CEO at Engine Biosciences
Katherine Wang

Katherine Wang

Project Director, Oncology at Ascendis Pharma A/S
Aleidy Silva

Aleidy Silva

Lead Field Applications Scientist at Berkeley Lights

Partners and Collaborators

Contact Us

We are passionate about what we do and if you have any interesting projects and ideas to share with us, feel free to send us an email or drop us a message in the contact form to the right.

Address: 83 Science Park Drive, The Curie, #02-03/04, Singapore 118258

Phone: +65 9730 2672

Email: press@kyantherapeutics.com